Ulcerative Colitis Therapeutics Market
Ulcerative Colitis Therapeutics Market Analysis By Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis), By Route of Administration (Oral, Injectables) & By Region - Global Market Insights 2021-2027
Analysis of Ulcerative Colitis Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Ulcerative Colitis Therapeutics Market Outlook (2021-2027)
The global ulcerative colitis therapeutics market is anticipated to rise at a CAGR of 5.1% from 2021 to 2027. In 2020, revenue from ulcerative colitis therapeutics was US$ 5.6 Bn, which is expected to reach US$ 7.9 Bn by 2027.
Market Size (2020)
US$ 5.6 Bn
Projected Year Value (2027)
US$ 7.9 Bn
Global Market Growth Rate (2021-2027)
China Market Growth Rate (2021-2027)
Key Companies Profiled
The ulcerative proctitis segment is projected to increase at a 4.7% CAGR from 2021 to 2027.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Demand Analysis of Ulcerative Colitis Therapeutics from 2017-2020 Vs Market Outlook for 2021-2027
“Increasing Prevalence of Ulcerative Colitis to Fuel Market Revenue”
The global market for ulcerative colitis therapeutics was valued at US$ 5.6 Bn in 2020.
Ulcerative colitis is a type of inflammatory bowel disease that affects a large number of people. It causes ulcers and inflammation in the digestive tract. The innermost lining of the large intestine and the rectum are affected by ulcerative colitis.
Ulcerative colitis can strike anyone at any age; however, it is most frequent in persons aged 15 to 30. The symptoms of ulcerative colitis differ from person to person, but they may include diarrhea, blood in the stool, and immunological response in the abdomen.
Abdominal cramping, nausea, fever, skin ulcers, loss of appetite, weight loss, joint pain, and weariness are all signs of ulcerative colitis. Hemorrhage, colon rupture, and the development of colon cancer are all serious complications of ulcerative colitis.
Around 20% of persons with ulcerative colitis or Crohn's disease, which is also a kind of IBD, have a family relative who has the condition. There is currently no cure for ulcerative colitis. However, some treatments can help to lessen the signs and symptoms of ulcerative colitis and perhaps bring about long-term remission.
Due to an increase in the frequency of ulcerative colitis and increased research and development to produce revolutionary ulcerative colitis treatments, the global ulcerative colitis therapeutics market is predicted to grow significantly.
All of these factors are expected to drive the market at 5.1% CAGR from 2021 to 2027.
Which Key Market Contributors are Driving Demand for Ulcerative Colitis Therapeutics?
“Continuous Advancements in Novel Treatments Boosting Market Growth”
The existence of enhanced ulcerative colitis therapies as a result of recent advancements, as well as the growing patient pool in need of treatment, are two main catalytic drivers driving the ulcerative colitis market forward.
Increased demand for symptomatic treatments, the influx of enhancing medications into the market, and increased acceptance of steroids and biologics to treat ulcerative colitis are all contributing to the industry growth.
Due to increased demand for ulcerative colitis therapeutic drugs, a shortage of medication, tailored therapy, and curative therapy for ulcerative colitis, the ulcerative colitis industry is likely to offer attractive market prospects.
Increased research and development efforts by public and private healthcare institutions are likely to increase opportunities for ulcerative colitis market participants.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What are the Challenging Factors for Market Expansion?
“Unfavorable Legislations & Expiration of Drug Patents Hampering Market Value Growth”
The market for ulcerative colitis therapeutics is projected to be constrained by the expiration of drug patents and strict government norms and regulations for biosimilar licensing. The market is additionally hampered by unfavorable legislation and policies, as well as varying circumstances in different nations.
Lack of understanding of the disease, and significant limitations of existing therapy choices could all operate as roadblocks for ulcerative colitis therapeutic solutions providers.
Which Region Dominates the Global Ulcerative Colitis Therapeutics Market?
“Rising Demand for Advanced Medical Technologies Driving Industry Growth in North America”
North America is likely to lead the ulcerative colitis therapeutics market because of the presence of prominent players and the rising frequency of ulcerative colitis in the region, as well as continued financing for the discovery of new therapies for the treatment of diseases.
The market is growing due to the rising demand for novel medical technologies and the presence of adequate medical facilities.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Why is the U.S. an Important Market for Ulcerative Colitis Therapeutic Drug Providers?
“High Availability of Treatment Choices Stimulating Market Expansion”
The U.S. ulcerative colitis therapeutics market was valued at US$ 1.7 Bn in 2020 and is projected to increase at the highest CAGR over the forecast period. In the United States, ulcerative colitis affects between 250,000 and 500,000 people, with an annual incidence of 8 to 12 per 100,000 people that has been stable over the last five decades.
The market is expected to grow significantly over the projected period due to wide availability of treatment choices, high healthcare spending, prevalence of diagnostic techniques that lead to early disease diagnosis, and an established healthcare system.
What is the Outlook for the China Ulcerative Colitis Therapeutics Market?
“Significant Healthcare Expenditure by Government Entities to Boost Market Value”
The market in China is expected to reach a valuation of US$ 1.4 Bn by 2027, representing a 4.8% CAGR from 2021 to 2027. The market in China is expected to be highly attractive over the forecast period, due to increased product approvals and high disposable income.
Market growth is being driven by a growing focus on developing healthcare facilities, economic growth, enhanced healthcare services, and the government's supportive policies.
Which Disease Type Shows the Highest Potential for Ulcerative Colitis Therapeutics?
“Innovative Therapeutics for Ulcerative Proctitis Driving Market Revenue”
The ulcerative proctitis segment is projected to record a 4.7% CAGR and reach US$ 2.1 Bn over the forecast period. One of the types of ulcerative colitis is ulcerative proctitis. Fine ulcerations in the inner linings of the large intestine mucosa are visible, and it is thought to be the first sign of ulcerative proctitis.
The segment is expected to grow due to increased research & development initiatives in the discovery of innovative therapeutics for ulcerative proctitis. Market revenue is being boosted by a growth in the number of inflammatory bowel diseases, ulcerative proctitis diseases, and the development of new ulcerative proctitis medications in clinical laboratories.
Which Route of Administration Enjoys High Preference?
“Oral Route of Administration More Preferred Owing to Strong Presence of Oral Pipeline Products”
The oral route of administration is expected to grow at the fastest rate over the forecast period. The approval of innovative medications for the treatment of ulcerative colitis, as well as the strong presence of oral pipeline products for the treatment of ulcerative colitis, have contributed to the segment growth.
Because of increased R&D efforts in the pharmaceutical and medical device industries, increased demand for pharmaceuticals required for treatment, and increased use of various types of ulcerative colitis drugs, the oral route of administration segment is expected to grow significantly.
COVID-19 Impact on Sales of Ulcerative Colitis Therapeutic Medications
The COVID-19 pandemic negatively impacted the ulcerative colitis therapeutics market. Outpatient visits, optional surgeries, and international patients all dropped sharply in the healthcare industry. As a result of the delayed procedures for ulcerative colitis treatment, the production of drugs for ulcerative colitis disease dropped.
Key companies working strategically in the clinical stage of development for ulcerative colitis will lead to a significant increase in market size over the forecast period. Rising advances in ulcerative colitis treatment, the emergence of biosimilars, and increasing drug approvals & launches are expected to drive the market growth over the coming years.
The market for ulcerative colitis therapeutics is highly competitive. Certain strategic efforts, such as mergers, new product launches, acquisitions, and collaborations, are implemented by key players to help them increase their market position.
For instance :
- In May 2021, The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's Zeposia (ozanimod) for the treatment of individuals with moderately to highly active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
Key Segments Covered in Ulcerative Colitis Therapeutics Industry Research
By Disease Type :
- Ulcerative Proctitis
- Left-sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
By Route of Administration :
By Region :
- North America
- Asia Pacific
- Latin America
- FAQs -
The global ulcerative colitis therapeutics market reached a valuation of US$ 5.86 Bn in 2021.
The global ulcerative colitis therapeutics market is estimated to expand at a CAGR of 5.1% from 2021 to 2027.
Abbott Laboratories, Inc., AstraZeneca PLC, Avaxia Biologics, Inc., BioLineRx Ltd., and Astellas Pharma, Inc. are key providers of ulcerative colitis therapeutic products.
The U.S., Canada, Germany, Japan, and China are expected to drive most demand for ulcerative colitis therapeutics.
The global market for ulcerative colitis therapeutics is expected to be valued at US$ 7.9 Bn by 2027.
High global incidence and prevalence of ulcerative colitis, technological advancements, and increase in patient assistance programs are driving market growth.